Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology

Hepatology

Volumn 45, Issue 6, 2007, Pages 1413-1421

  Ng, Teresa I ^a   Mo, Hongmei ^a   Pilot Matias, Tami ^a   He, Yupeng ^a   Koev, Gennadiy ^a   Krishnan, Preethi ^a   Mondal, Rubina ^a   Pithawalla, Ron ^a   He, Wenping ^a   Dekhtyar, Tanya ^a   Packer, Jeremy ^a   Schurdak, Mark ^a   Molla, Akhteruzzaman ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN 2; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE IDENTIFICATION; GENE LIBRARY; HEPATITIS C VIRUS; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

DRUG DESIGN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, VIRAL; GENE LIBRARY; GENETIC SCREENING; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; REPLICON; RNA, SMALL INTERFERING; RNA, VIRAL; VIRUS REPLICATION;

EID: 34250354423     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21608     Document Type: Article

References (50)

1. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000;20:1-16.
2. Seeff LB. Natural history of chronic hepatitis C. HEPATOLOGY 2002; 36(Suppl):S35-S46.
3. Jin DY, Wang HL, Zhou Y, Chun AC, Kibler KV, Hou YD, et al. Hepatitis C virus core protein-induced loss of LZIP function correlates with cellular transformation. Embo J 2000;19:729-740.
4. Kato N, Lan KH, Ono-Nita SK, Shiratori Y, Omata M. Hepatitis C virus nonstructural region 5A protein is a potent transcriptional activator. J Virol 1997;71:8856-8859.
5. Saito K, Meyer K, Warner R, Basu A, Ray RB, Ray R. Hepatitis C virus core protein inhibits tumor necrosis factor alpha-mediated apoptosis by a protective effect involving cellular FLICE inhibitory protein. J Virol 2006; 80:4372-4379.
6. Street A, Macdonald A, Crowder K, Harris M. The Hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade. J Biol Chem 2004;279:12232-12241.
7. Tan SL, Nakao H, He Y, Vijaysri S, Neddermann P, Jacobs BL, et al. NS5A, a nonstrucrural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ ligand-dependent manner and perturbs mitogenic signaling. Proc Natl Acad Sci U S A 1999;96:5533-5538.
8. Yoshida T, Hanada T, Tokuhisa T, Kosai K, Sata M, Kohara M, Yoshimura A. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med 2002;196:641-653.
9. Hoofnagle JH. Course and outcome of hepatitis C. HEPATOLOGY 2002; 36(Suppl):S21-S29.
10. Seeff LB, Hoofnagle JH. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis 2003;7:261-287.
11. Kukolj G, McGibbon GA, McKercher G, Marquis M, Lefebvre S, Thauvette L, et al. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J Biol Chem 2005;280:39260-39267.
12. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003;426:186-189.
13. Lin K, Perni RB, Kwong AD, Lin C. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob Agents Chemother 2006;50:1813-1822.
14. Malcolm BA, Liu R, Lahser F, Agrawal S, Belanger B, Butkiewicz N, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006; 50:1013-1020.
15. Mo H, Lu L, Pilot-Matias T, Pithawalla R, Mondal R, Masse S, Dekhtyar T, et al. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob Agents Chemother 2005;49:4305-4314.
16. Klumpp K, Leveque V, Le Pogam S, Ma H, Jiang WR, Kang H, et al. The novel nucleoside analog R1479 (4′-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem 2006;281:3793-3799.
17. Lin C, Gates CA, Rao BG, Brennan DL, Fulghum JR, Luong YP, et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2005; 280:36784-36791.
18. Lin C, Lin K, Luong YP, Rao BG, Wei YY, Brennan DL, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 2004;279:17508-17514.
19. Lu L, Pilot-Matias TJ, Stewart KD, Randolph JT, Pithawalla R, et al. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob Agents Chemother 2004;48:2260-2266.
20. Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006;70:28-38.
21. Yi M, Tong X, Skelton A, Chase R, Chen T, Prongay A, et al. Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem 2006;281:8205-8215.
22. Le Pogam S, Jiang WR, Leveque V, Rajyagutu S, Ma H, Kang H, et al. In vitro selected Con1 subgenomic replicons resistant to 2′-C-Methyl- Cytidine or to R1479 show lack of cross resistance. Virology 2006;351:349-359.
23. Le Pogam S, Kang H, Harris SF, Leveque V, Giannetti AM, Ali S, et al. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J Virol 2006;80:6146-6154.
24. Yi M, Bodola F, Lemon SM. Subgenomic hepatitis C virus replicons inducing expression of a secreted enzymatic reporter protein. Virology 2002;304:197-210.
25. Blight KJ, McKeating JA, Marcotrigiano J, Rice CM. Efficient replication of hepatitis C virus genotype 1 a RNAs in cell culture. J Virol 2003;77: 3181-3190.
26. Grobler JA, Markel EJ, Fay JF, Graham DJ, Simcoe AL, Ludmerer SW, et al. Identification of a key determinant of hepatitis C virus cell culture adaptation in domain II of NS3 helicase. J Biol Chem 2003;278:16741-16746.
27. Chung RT, He W, Saquib A, Contreras AM, Xavier RJ, Chawla A, et al. Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system. Proc Natl Acad Sci U S A 2001;98:9847-9852.
28. Kapadia SB, Brideau-Andersen A, Chisari FV. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci U S A 2003;100:2014-2018.
29. Seo MY, Abrignani S, Houghton M, Han JH. Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. J Virol 2003;77:810-812.
30. Ng TI, Shi Y, Huffaker HJ, Kari W, Liu Y, Chen CM, et al. Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethy)butyl]guanine. Antimicrob Agents Chemother 2001;45:1629-1636.
31. Bourne N, Pyles RB, Yi M, Veselenak RL, Davis MM, Lemon SM. Screening for hepatitis C virus antiviral activity with a cell-based secreted alkaline phosphatase reporter replicon system. Antiviral Res 2005;67:76-82.
32. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003;5: 834-839.
33. Breiman A, Grandvaux N, Lin R, Ottone C, Akira S, Yoneyama M, et al. Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon. J Virol 2005;79:3969-3978.
34. Foy E, Li K, Wang C, Sumpter R Jr, Ikeda M, Lemon SM, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003;300:1145-1148.
35. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 2005;102:2992-2997.
36. Schneider K, Potter KG, Ware CF. Lymphotoxin and LIGHT signaling pathways and target genes. Immunol Rev 2004;202:49-66.
37. Girard S, Vossman E, Misek DE, Podevin P, Hanash S, Brechot C, et al. Hepatitis C virus NS5A-regulated gene expression and signaling revealed via microarray and comparative promoter analyses. HEPATOLOGY 2004;40: 708-718.
38. Waris G, Livolsi A, Imbert V, Peyron JF, Siddiqui A. Hepatitis C virus NS5A and subgenomic replicon activate NF-kappaB via tyrosine phosphorylation of IkappaBalpha and its degradation by calpain protease. J Biol Chem 2003;278:40778-40787.
39. Park KJ, Choi SH, Lee SY, Hwang SB, Lai MM. Nonstructural 5A protein of hepatitis C virus modulates tumor necrosis factor alpha-stimulated nuclear factor kappa B activation. J Biol Chem 2002;277: 13122-13128.
40. Chen CM, You LR, Hwang LH, Lee YH. Direct interaction of hepatitis C virus core protein with the cellular lymphotoxin-beta receptor modulates the signal pathway of the lymphotoxin-beta receptor. J Virol 1997;71: 9417-9426.
41. Matsumoto M, Hsieh TY, Zhu N, VanArsdale T, Hwang SB, Jeng KS, et al. Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor. J Virol 1997;71:1301-1309.
42. Waris G, Tardif KD, Siddiqui A. Endoplasmic reticulum (ER) stress: hepatitis C virus induces an ER-nucleus signal transduction pathway and activates NF-kappaB and STAT-3. Biochem Pharmacol 2002;64:1425-1430.
43. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci U S A 2001;98:9599-9604.
44. Tardif KD, Waris G, Siddiqui A. Hepatitis C virus, ER stress, and oxidative stress. Trends Microbiol 2005;13:159-163.
45. Choi J, Lee KJ, Zheng Y, Yamaga AK, Lai MM, Ou JH. Reactive oxygen species suppress hepatitis C virus RNA replication in human hepatoma cells. HEPATOLOGY 2004;39:81-89.
46. Mercurio F, Manning AM. NF-kappaB as a primary regulator of the stress response. Oncogene 1999;18:6163-6171.
47. Macdonald A, Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 2004;85:2485-2502.
48. Bowie AG, Haga IR. The role of Toll-like receptors in the host response to viruses. Mol Immunol 2005;42:859-867.
49. Hiscott J, Grandvaux N, Sharma S, Tenoever BR, Servant MJ, Lin R. Convergence of the NF-kappaB and interferon signaling pathways in the regulation of antiviral defense and apoptosis. Ann N Y Acad Sci 2003;1010:237-248.
50. Kalamvoki M, Mavromara P. Calcium-dependent calpain proteases are implicated in processing of the hepatitis C virus NS5A protein. J Virol 2004;78:11865-11878.